Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, Coffman KT, Walsh W, Ready S, Cook K, Damschroder M, Kinch M, Kiener PA, Woods R, Gao C, Dall'Acqua W, Wu H, Coats S. Bruckheimer EM, et al. Neoplasia. 2009 Jun;11(6):509-17, 2 p following 517. doi: 10.1593/neo.81578. Neoplasia. 2009. PMID: 19484140 Free PMC article.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Cohen EEW, et al. Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Lancet. 2019. PMID: 30509740 Clinical Trial.
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Paz-Ares L, et al. N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280635 Free article. Clinical Trial.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Gandhi L, et al. N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16. N Engl J Med. 2018. PMID: 29658856 Free article. Clinical Trial.
Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.
Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M Jr, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN Jr, Gandara DR, Perez-Soler R. Li T, et al. Among authors: walsh wv. Clin Lung Cancer. 2017 Jan;18(1):60-67. doi: 10.1016/j.cllc.2016.10.003. Epub 2016 Oct 28. Clin Lung Cancer. 2017. PMID: 27919627 Free PMC article. Clinical Trial.
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.
Schwind S, Edwards CG, Nicolet D, Mrózek K, Maharry K, Wu YZ, Paschka P, Eisfeld AK, Hoellerbauer P, Becker H, Metzeler KH, Curfman J, Kohlschmidt J, Prior TW, Kolitz JE, Blum W, Pettenati MJ, Dal Cin P, Carroll AJ, Caligiuri MA, Larson RA, Volinia S, Marcucci G, Bloomfield CD; Alliance for Clinical Trials in Oncology. Schwind S, et al. Blood. 2013 Jan 10;121(2):385-91. doi: 10.1182/blood-2012-07-442772. Epub 2012 Nov 16. Blood. 2013. PMID: 23160462 Free PMC article.
18 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page